Nature Communications findings showed NR2F6 deletion revived exhausted CAR-T cells and boosted activity against solid tumors. In murine models, modified cells drove tumor regression, prolonged survival and resistance to rechallenge.
Korean biotech firms will present next-generation cancer therapies at the AACR meeting, including CAR-T platforms for solid tumors, mRNA-based treatments, radiopharmaceuticals, and bispecific antibody ADCs. Companies like AbClon, Verismo Therapeutics, Hanmi Pharmaceutical, and SK Biopharmaceuticals will showcase their latest research.
The global cancer gene therapy market is projected to grow from $3.6 billion in 2023 to $16 billion by 2033 at a 16.1% CAGR, while the broader oncology market eyes $748 billion by 2035, driven by immunotherapy advances and targeted treatments.
The global oncology market is projected to nearly triple from $279.98 billion in 2026 to $748.17 billion by 2035, driven by rapid adoption of immunotherapy, checkpoint inhibitors, and cell therapies across solid tumors and hematologic cancers.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03512340 |
Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers |
COMPLETED | PHASE1 |
| NCT02304809 |
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT02034981 |
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 |
COMPLETED | PHASE2 |
| NCT01775072 |
Genomic Profiling in Cancer Patients |
RECRUITING |
